Morningside Ventures has led a $30m series A round for Emory University spinout Meissa Vaccines, a current resident in Johnson & Johnsons’ JLabs incubator.

Meissa Vaccines, a US-based developer of vaccines for viral respiratory infections based on research at Emory University, completed a $30m series A round yesterday led by Morningside Ventures.
Founded in 2014, Meissa’s platform exploits synthetic biology and genetic engineering to rapidly generate vaccines for respiratory conditions. The spinout expects its vaccines will be safer and induce a more efficient immune response than natural pathogens.
Meissa advances research by CEO Martin Moore, associate professor at Emory University and director…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in